Stakeholder Opinions: Head And Neck Cancer

Published by: Datamonitor

Published: Nov. 27, 2007 - 96 Pages

Table of Contents

ABOUT DATAMONITOR HEALTHCARE

About the Oncology pharmaceutical analysis team

CHAPTER 1 EXECUTIVE SUMMARY

Scope of the analysis

Datamonitor insight into the head and neck cancer market

Related reports

Upcoming reports

CHAPTER 2 HEAD AND NECK CANCER OVERVIEW

Introduction

Anatomy of the head and neck

Symptoms of head and neck cancer

Subtypes

Paranasal sinuses and nasal cavity cancers

Oral cavity cancers

Salivary gland cancer

Pharyngeal cancers

Laryngeal cancers

Staging head and neck cancer

Tumor, nodes and metastasis classification for head and neck cancer

Risk factors in head and neck cancer

Tobacco and alcohol independently increase risk

Human papilloma virus exposure

Diet may be important in nasopharyngeal cancer

Epidemiology

Crude incidence rates for head and neck cancers

Incidence of head and neck cancer by gender in 2007

Head and neck cancer is more prevalent in males

Forecast incidence for head and neck cancer by subtype to 2016

Incidence of head and neck cancer subtypes by country in 2007

Oral cancers account for 44% of all head and neck cancers across the 7MM

Human papilloma virus may increase head and neck cancer incidence

CHAPTER 3 CURRENT TREATMENT OPTIONS FOR HEAD AND NECK CANCER

Head and neck cancer treatment overview

Radiotherapy is the cornerstone of head and neck cancer treatment

Intensity modulated radiation therapy

Chemoradiotherapy (CRT): cisplatin sets the standard

Single-agent based chemoradiotherapy (CRT)

Multi-agent based chemoradiotherapy (CRT)

Cisplatin, 5-flurouracil and radiotherapy

Cisplatin, paclitaxel and radiotherapy

5-fluorouracil, hydroxyurea and radiotherapy (FHX)

Paclitaxel, 5-fluorouracil, hydroxyurea and radiotherapy (TFHX)

Can induction chemotherapy control distant metastasis?

Taxotere sets a new induction standard

Paclitaxel-based induction therapy

Erbitux advances SCCHN treatment

Clinical trial results for Erbitux in SCCHN

Phase III Erbitux trial meets primary endpoint

Bristol-Myers Squibb/ImClone/Merck Serono anticipate further Erbitux efficacy data

HPV status may influence choice of SCCHN treatment

CHAPTER 4 UNMET NEEDS & TREATMENT CONTROVERSIES IN HEAD AND NECK CANCER

Intolerable toxicities associated with current treatment options

Poor outcome still remains for patients with metastatic disease

Current SCCHN treatment requires standardization

Identifying responder groups for targeted therapy in SCCHN

Conclusions

CHAPTER 5 HEAD AND NECK CANCER PRODUCT PIPELINE

Head and neck cancer pipeline overview

Pipeline overview

Late-phase product pipeline for head and neck cancer

Phase II product pipeline for head and neck cancer

Phase I product pipeline for head and neck cancer

Late-phase cytotoxic drug profile

Lipoplatin (Regulon)

Drug overview

Key historical events

Clinical trial data

Datamonitor comments

Late-phase molecular targeted therapy drug profiles

Proxinium (VB4-845; Viventia Biotech)

Drug overview

Key historical events

Clinical trial data

Datamonitor comments

Tykerb (lapatinib; GlaxoSmithKline)

Drug overview

Key historical events

Clinical trial data

Datamonitor comments

Vectibix (panitumumab; Amgen),

Drug overview

Key historical events

Clinical trial data

Datamonitor comments

Zalutumumab (HuMax-EGFr; Genmab)

Drug overview

Key historical events

Clinical trial data

Datamonitor comments

Late-phase gene therapy drug profile

Advexin (INGN-201; Introgen Therapeutics)

Drug overview

Key historical events

Clinical trial data

Datamonitor comments

APPENDIX

Bibliography

Journals

Websites

Other

Key opinion leaders

Abbreviations

List of tables

List of figures

About Datamonitor

About Datamonitor Healthcare

About the Oncology analysis team

Disclaimer

List of Tables

Table 1: AJCC nodes and metastasis classification for head and neck cancer

Table 2: AJCC primary tumor classification of head and neck cancers

Table 3: Crude incidence rates (per 100,000) of head and neck cancers, 2002

Table 4: Forecast incidence of head and neck cancers, 2002-2016

Table 5: Overview of chemotherapy regimens commonly used in combination with radiotherapy in head and neck cancer

Table 6: A randomized study of adjuvant treatment with cisplatin-based chemoradiotherapy versus radiotherapy alone in 167 patients

Table 7: Overview of cisplatin-5-FU-based chemoradiotherapy regimens for SCCHN

Table 8: A Phase III RTOG trial of Erbitux with cisplatin-based CRT for the first-line treatment of patients with locally advanced SCCHN

Table 9: Treatment-related toxicities in SCCHN

Table 10: Pipeline drugs in Phase III development for head and neck cancer, 2007

Table 11: Pipeline drugs in Phase II development for head and neck cancer, 2007

Table 12: Pipeline drugs in Phase I development for head and neck cancer, 2007

Table 13: Lipoplatin: Key historical events

Table 14: Ongoing clinical trials for Lipoplatin in advanced head and neck cancer, 2007

Table 15: Proxinium: Key historical events

Table 16: Ongoing clinical trials involving Proxinium in head and neck cancer, 2007

Table 17: Tykerb: Key historical events

Table 18: Tykerb clinical trials in head and neck cancer, 2007

Table 19: Vectibix: Key historical events

Table 20: Vectibix clinical trials in head and neck cancer, 2007

Table 21: Zalutumumab: Key historical events

Table 22: Ongoing clinical trials for zalutumumab in head and neck cancer, 2007

Table 23: Phase I/II study results of zalutumumab in recurrent SCCHN

Table 24: Advexin: Key historical events

Table 25: Ongoing clinical trials for Advexin in head and neck cancer, 2007

Table 26: Abbreviations used in Stakeholder Opinions: Head and Neck Cancer, 2007

List of Figures

Figure 1: Anatomy of the head and neck

Figure 2: Positioning of the paranasal sinuses

Figure 3: The three major salivary glands

Figure 4: Subdivisions of the pharynx

Figure 5: Incidence of head and neck cancers by gender, 2007

Figure 6: Incidence trends of head and neck cancer subtypes, 2002-2016

Figure 7: Incidence of head and neck cancer subtypes in the seven major pharmaceutical markets, 2007

Figure 8: Treatment algorithm for SCCHN

Figure 9: A randomized Phase III trial of Taxotere-based induction chemotherapy in patients with Stage III/IV SCCHN

Figure 10: Preliminary Phase III trial results for paclitaxel induction therapy and CRT in 384 locally advanced SCCHN patients

Figure 11: Phase III trial results for Erbitux and radiotherapy in the first-line treatment in patients with Stage III/IV SCCHN

Figure 12: Phase III trial results for Erbitux and chemotherapy in the first-line treatment of recurrent/metastatic SCCHN patients

Figure 13: Phase II trial results for Erbitux and cisplatin-based chemoradiotherapy in the first-line treatment of locoregionally advanced SCCHN

Figure 14: 5-year survival rates (%) for SCCHN patients according to disease stage

Figure 15: Preliminary Phase III results for Lipoplatin in advanced head and neck cancer

Figure 16: Phase I results for Proxinium in advanced SCCHN

Figure 17: Phase II results of Tykerb in recurrent/metastatic SCCHN

Figure 18: Preliminary Phase I results for Vectibix in late-stage head and neck cancer

Figure 19: Phase II trial results for Advexin in recurrent SCCHN

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.